Alerta

NOVEL DNA METHYLATION MARKER TAGME-5 FOR TUMOR IDENTIFICATION AND USE THEREOF

Resumen de: WO2025073216A1

Provided are a novel DNA methylation marker TAGMe-5 for tumor identification and a use thereof. The tumor marker TAGMe-5 shows a significant DNA methylation difference in para-carcinoma tissues and carcinoma tissues, the difference has remarkable statistical significance, and the difference is shown in a plurality of tumors such as solid tumors and non-solid tumors. The solid tumors comprise lung cancer, liver cancer, prostate cancer, cervical cancer, endometrial cancer, urothelial carcinoma, a biliary tract tumor, etc. The non-solid tumors comprise a blood system tumor, lymphoma, etc. Therefore, the tumor marker can be used for screening, molecular diagnosis, prognosis, and therapeutic effect evaluation for clinical multi-tumors (Pan-cancer).

COMBINATION THERAPIES WITH A CELL THERAPY EXPRESSING A GPRC5D-TARGETING CAR AND RELATED METHODS AND USES

Resumen de: WO2025076472A1

Provided herein are methods and uses of combination therapies involving GPRC5D- targeted cell therapy comprising chimeric antigen receptors (CARs), which contain extracellular antigen-binding domains that bind to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D), and a combination agent, e.g. an immunomodulatory compound, for treating subjects with cancers such as multiple myeloma, and related methods, uses, and articles of manufacture.

MODULATING THE TUMOR IMMUNE MICROENVIRONMENT VIA TARGETING REGULATORY T CELLS (TREGS) WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY

Resumen de: WO2025076471A2

Disclosed are chimeric antigen receptors that target glycoprotein A repetitions predominant (GARP) and methods of their use in the treatment of cancer including, but not limited to breast cancer, bladder cancer, glioblastoma, or leukemia or other malignancies characterized with GARP+ Tregs.

FOLLICULAR LYMPHOMA TRANSCRIPTOMIC CLASSIFIER

Resumen de: WO2025076428A1

The present disclosure relates to a method for classifying a subject diagnosed with follicular lymphoma (FL) into 7 FL subtypes (FL1-FL7) and related methods of treating a subject diagnosed with FL. The present disclosure further includes related compositions, e.g., isolated probes and primers, as well as kits and arrays comprising same. A therapy guidance software tool is also disclosed.

HIGH THROUGHPUT PARALLEL SYNTHESIS OF SMALL MOLECULE DEGRADERS

Resumen de: WO2025076501A1

Disclosed herein are high throughput synthetic methods for the deliberate and prospective discovery of molecular glues which can be used to form composite protein-ligand surfaces that facilitate interfacial binding to other proteins over dispersed surfaces. In particular, this application discloses a high throughput approach using sulfur(VI) fluoride exchange (SuFEx) transformations and N-hydroxysuccinimide (NHS)-ester derived amide couplings to prospectively repurpose known ligands for a prolein-of-interest into degraders and compounds capable of inducing proximity to other proteins. Disclosed herein are methods of developing known ligands of a target protein into degraders of the target proteins. Further disclosed are methods of developing novel small molecule chromatin-competitive inhibitors of the eleven nineteen leukemia (ENL) YEATS domain into effective degraders of ENL.

BCL-2 eIF4A A pharmaceutical composition for treating lymphoma containing a BCL-2 inhibitor a selective extranuclear transport protein inhibitor and an eIF4A inhibitor

Resumen de: WO2025071306A1

The present invention relates to a pharmaceutical composition for treating cancer in which an elF4A inhibitor and at least one of a BCL-2 inhibitor or a selective export protein (XPO-1) inhibitor are used in a combination regimen. The present invention relates to a pharmaceutical composition for treating cancer, wherein the elF4A inhibitor is one selected from the group consisting of silvestrol, CR-1-3B, zotatifin, rohinitib, didesmethylrocaglamide, and episylvestrol, and used in a combination regimen with at least one of a BCL-2 inhibitor or a selective nuclear export protein inhibitor.

APPROVED PRODUCTS FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Resumen de: US2025109198A1

Described herein are approved products and methods of using approved products for treating relapsed or refractory multiple myeloma in a patient. Also described herein are methods of selling or offering for sale an approved product.

BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA DIAGNOSTIC TEST

Resumen de: US2025110131A1

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma that can develop around breast implants. The disclosure is directed towards devices and methods for diagnose BIA-ALCL from the seroma (fluid) surrounding the implant using a lateral flow assay (LFA) detecting CD30 and/or one or more cytokines known to be produced by tumor cells in BIA-ALCL.

COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA

Resumen de: AU2021239828A1

This invention relates to compounds for treating acute myeloid leukemia or inhibiting recurrence of acute myeloid leukemia and for inhibiting growth of and/or killing leukemic stem cells.

CONTINUOUS DELIVERY OF LENALIDOMIDE AND OTHER IMMUNOMODULATORY AGENTS

Resumen de: US2025108043A1

Provided are systems and methods for continuously administering to a subject in need of treatment a formulation comprising an immunomodulatory imide compound. In some embodiments, the method are for use in treating multiple myeloma, transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes, mantle cell lymphoma, hematologic cancers, or solid tumor cancers.

COMPOSITIONS FOR TREATING HEMATOLOGICAL CONDITIONS AND METHODS OF MAKING AND USING THE SAME

Resumen de: WO2025072692A1

Compositions for treating hematological conditions such as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) are provided. In particular, a population of CD8+ T lymphocytes with cytotoxic activity against leukemia cells is provided, as well as methods of isolating and enriching such cells for therapeutic applications.

IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORME

Resumen de: AU2025201932A1

Abstract The present disclosure provides compositions and methods useful for treating Glioblastoma Multiforme (GBM), e.g., compositions comprising virus-like particles (VLPs) comprising Moloney Murine leukemia virus (MMLV) core proteins and the human cytomegalovirus epitopes, gB and pp65, formulated with GM-CSF, which, at dose of at least 10 pg gB/pp65Gag, reverse dysregulation of anti-HCMV immunity in GBM patients. 21570040_1 (GHMatters) P117888.AU.1

METHODS OF TREATING CANCERS AND ENHANCING EFFICACY OF BCMAXCD3 BISPECIFIC ANTIBODIES

Resumen de: US2025109211A1

Disclosed are methods of treating cancers and enhancing efficacy of BCMAxCD3 bispecific antibodies. In particular, methods are disclosed of using a BCMAxCD3 bispecific antibody, an anti-CD38 antibody and/or pomalidomide to treat cancers, particularly relapsed or refractory multiple myeloma.

ENRICHED T-CELL POPULATIONS

Resumen de: WO2025072081A1

Provided herein are systems, kits, and methods for generating an enriched T cell population from an initial peripheral blood mononuclear cell (PBMC) population using at least two types of cell-binding reagents: (e.g., particles conjugated to CD32, CD19, CD244, or CD25 binding agents), where the enriched T cell population is: i) enriched for desired T-cells (e.g., early memory T cells and naïve T cells), and ii) depleted in normal and malignant non-desired cells selected from: CD25hi regulatory T-cells (Tregs), CD25hi CLL cells, CD244 T-cells, CD32+ monocytes, CD32+ myeloid leukemia cells, CD32 basophils, CD19+ and/or CD32+ B cells, CD244+ natural killer (NK) cells, and myeloid cells). In certain embodiments, the enriched T cell populations are used for generating a population of chimeric antigen receptor (CAR) T-cells, T-cell receptor-engineered T cells, or Tumor-infiltrating T lymphocyte (ITL) products.

METHODS, REAGENTS AND KITS FOR DETECTING MINIMAL/MEASURABLE DISEASE IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND T-CELL LYMPHOBLASTIC LYMPHOMA (T-LBL)

Resumen de: WO2025071406A1

The invention relates to the field of leukemia/lymphoma diagnosis, more specifically to the detection of MRD in bone marrow, blood and other fluids and tissues from patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma (T-ALL/T-LBL). Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in T-ALL and/or T-LBL, the reagent composition comprising a panel of at least four antibodies conjugated to a detectable label, the panel comprising antibodies against markers NKp80, CD16, cyCD3 and smCD3.

METHOD TO PREDICT AML OUTCOME

Resumen de: WO2025068340A1

The present invention relates to a method for predicting the survival time of a patient suffering from an Acute Myeloid Leukemia (AML). In this study, the inventors used conditional Jam-3-deficient mice crossed with iMLL-AF9 leukemia model. They found that Jam-3-deficiency rewired the transcriptional program of leukemia initiating cells (LIC) with upregulation of genes belonging to AP-l/TNF-α pathways. Transposition of results to human allowed to determine a new prognosis score called ATIC for AP-l/TNF-α Initiating Cells, complementary and distinct from the LSC17 score. Thus, the invention relates to a method for predicting the survival time of a patient suffering from an Acute Myeloid Leukemia (AML) based on the determination in a sample obtained from the patient of the expression levels of at least 7 genes selected in the group consisting in: JAM3, DUSP1, JUN, IER2, DUSP2, RGS1, H2BC8, PTGS2, NFKBID, PPP1R15A, NFKBIZ, ZFP36, SNORA28, TPT1, KLF2, BTG2, JUNB, JUNE), ATF3, UBC, SKIL, TAF7, SLFN12L, NR4A1, CHST2, GASS, SNORA31, HES1, EGR3, RPS13, PMAIP1, RHOB, MYL9, ZNF699, ZNF101, FOS, FJX1, RPP25L, HEY1, PTMA, GIMAP4, EFCAB11, FOSE, CD14, CCL4, CCL3, PF4, OSM, CD69, ITGA2B, VWF, MYCN and F2RL2.

OXYGENATED HETEROCYCLIC LSD-1 INHIBITORS AND RELATED METHODS OF USE

Resumen de: WO2025072637A1

Disclosed herein is a class of small-molecules having oxygenated heterocyclic ring structure. Compounds disclosed herein are lysine demthylase-1 (LSD-1) inhibitors, and accordingly, also disclosed herein is the use the compounds as therapeutics for the treatment of hematological disorders (e.g., sickle cell disease (SCD), β-thalassemia), cancer (e.g., acute myeloid leukemia (AML), multiple myeloma, biliary tract cancer, non-small cell lung cancer (NSCLC), chronic lymphocytic leukemia, advanced solid tumor, advanced malignancies), and/or a neurological disorder (e.g., Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson disease (PD), Schizophrenia, Huntington disease (HD)), a metabolic disorder (e.g., type-2 diabetes (T2D), obesity) and other conditions related to LSD-1 activity (e.g., mild to moderate Alzheimer's disease, myocardial fibrosis, autism, complex neurodevelopmental diseases).

APPLICATION OF CSF1R INHIBITOR IN PREPARATION OF NK/T CELL LYMPHOMA TREATMENT DRUG

Resumen de: WO2025065747A1

Disclosed is an application of a CSF1R inhibitor in the preparation of an NK/T cell lymphoma treatment drug. Further disclosed are a use as an NK/T cell lymphoma marker, a use of a CSF1 detection reagent in the preparation of an NK/T cell lymphoma prognosis kit, and a use of the CSF1 detection reagent in the preparation of an NK/T cell lymphoma primary screening kit. The present invention can be promoted and applied to primary screening, prognosis and treatment of clinical NK/T cell lymphoma patients.

CBL-B INHIBITORS AND METHODS OF USES THEREOF

Resumen de: WO2025067468A1

Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.

PHARMACEUTICAL COMPOSITION FOR TREATING LYMPHOMA COMPRISING BCL-2 INHIBITOR, SELECTIVE NUCLEAR EXPORT PROTEIN INHIBITOR, AND ELF4A INHIBITOR

Nº publicación: WO2025071306A1 03/04/2025

Solicitante:

UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV [KR]
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8